The Temple Grandin Genome: Comprehensive Analysis in a Scientist with High-Functioning Autism

Rena J. Vanzo 1,*†, Aparna Prasad 1,†, Lauren Staunch 1, Charles H. Hensel 1, Moises A. Serrano 1, E. Robert Wassman 1, Alexander Kaplun 2, Temple Grandin 3 and Richard G. Boles 4

1 Lineagen, Inc., Salt Lake City, UT 84109, USA; aparna.ambastha@gmail.com (A.P.); laurenstaunch@gmail.com (L.S.); ghensel3@comcast.net (C.H.H.); mserrano@lineagen.com (M.A.S.); drwassman@icloud.com (E.R.W.)
2 Variantyx, Inc., Framingham, MA 01701, USA; alex.kaplun@variantyx.com
3 Department of Animal Science, Colorado State University, Fort Collins, CO 80523, USA; Cheryl.Miller@ColoState.EDU
4 The Center for Neurological and Neurodevelopmental Health, Voorhees, NJ 08043, USA; drboles@molecularnito.com
* Correspondence: rvanzo@lineagen.com
† These authors contributed equally to this work.

Abstract: Autism spectrum disorder (ASD) is a heterogeneous condition with a complex genetic etiology. The objective of this study is to identify the complex genetic factors that underlie the ASD phenotype and other clinical features of Professor Temple Grandin, an animal scientist and woman with high-functioning ASD. Identifying the underlying genetic cause for ASD can impact medical management, personalize services and treatment, and uncover other medical risks that are associated with the genetic diagnosis. Prof. Grandin underwent chromosomal microarray analysis, whole exome sequencing, and whole genome sequencing, as well as a comprehensive clinical and family history intake. The raw data were analyzed in order to identify possible genotype-phenotype correlations. Genetic testing identified variants in three genes (SHANK2, ALX1, and RELN) that are candidate risk factors for ASD. We identified variants in MEFV and WNT10A, reported to be disease-associated in previous studies, which are likely to contribute to some of her additional clinical features. Moreover, candidate variants in genes encoding metabolic enzymes and transporters were identified, some of which suggest potential therapies. This case report describes the genomic findings in Prof. Grandin and it serves as an example to discuss state-of-the-art clinical diagnostics for individuals with ASD, as well as the medical, logistical, and economic hurdles that are involved in clinical genetic testing for an individual on the autism spectrum.

Keywords: autism spectrum disorder; genetic testing; chromosomal microarray analysis; whole exome sequencing; whole genome sequencing; clinical utility; polygenic risk scores; Temple Grandin

1. Introduction

Autism spectrum disorder (ASD) is one of the most common neurodevelopmental disorders characterized by impairments in communication and social interaction and the presence of restrictive and repetitive behaviors [1]. The American College of Medical Genetics and Genomics (ACMG) recommends genetic evaluation for individuals with ASD [2]. Discovering the underlying genetic cause for ASD can improve the care and management by personalizing services and treatment, including addressing the medical risks that are associated with the genetic diagnosis [3]. We performed chromosomal microarray (CMA), as well as whole exome and genome sequencing (WES, WGS), on our co-author, Prof. Temple Grandin (T.G.), a widely recognized animal scientist and woman with high-functioning ASD, who is renowned for her insights on the condition. While using this report of the genomic findings in T.G., we create a discourse on state-of-the-art diagnostics for individuals with ASD. Predictably, we found many variants of uncertain significance (VUSs).
However, we also identified the variants that were previously reported in the literature as pathogenic/disease-causing and overlap with her clinical features. Furthermore, many of these variants lie in genes that will personalize medical management and guide potential therapeutic options, which underscores the importance of clinical genetic testing in those with ASD.

2. Materials and Methods

2.1. Case Report

T.G. was a full-term female infant born in 1947 after an uncomplicated pregnancy, labor, and delivery. She had normal muscle tone and early motor milestones. However, she did not make eye contact and had touch sensitivity and aversion, including stiffening up when held by others. Even based on these specific features, ASD was not suggested as the diagnostic entity had only been described four years previously [4]. A neurologist performed an electroencephalogram and ruled out petit mal epilepsy, and a hearing test was normal. T.G. was diagnosed with “minimal brain damage” at two years old. At two and a half years old, expressive and receptive language delays were noted (she was non-verbal), and she was enrolled in speech therapy. With intensive treatment and emphasis on turn-taking games, she began speaking at age three and a half and was fully verbal by age four. She maintained typical autistic behaviors, such as repetitively dribbling sand through her hands at the beach and tantrums after sudden loud noises. The associated issues included stuttering and challenges with auditory and sensory integration. In particular, touch aversion improved with the use of a squeezing machine during childhood, which T.G. designed and has adapted in order to improve ethical animal husbandry management [5]. She also reported difficulties with social interactions in childhood and adolescence. The diagnosis of autism came later in elementary school by a psychiatrist. At age nine years and at age twelve years, her IQ was tested with the Wechsler. Her full-scale IQ was 120 on the first test and 137 on the second test. The measurement of cognitive abilities ranged from disability to gifted; for example, cognitive skills that require visualization, including block design and puzzle completion, were superior, whereas auditory integration was reduced [5,6]. T.G. received a Ph.D. and has been highly successful in her career regarding animal behavior-informed agriculture design prior to her career lecturing on ASD. Despite the absence of formal testing for ASD (based on age), T.G. meets current diagnostic criteria for ASD or intellectual disability in other family members. However, T.G.’s maternal grandmother was medicated for anxiety, and T.G. suspects that her father had high-functioning ASD. Both of T.G.’s parents held college degrees, and her maternal grandfather had particular academic success as an MIT-trained engineer and co-inventor of the autopilot for airplanes. The remainder of the family history is non-contributory without a suggested inheritance pattern; further details on family history is withheld in order to maintain privacy.

T.G. reports a substantial, decades-long history of chronic myalgia, muscle rigidity, paresthesia, and hyperesthesia of the feet, as well as sudden episodes of feeling “boiling hot”. She reports coordination difficulties and tires easily with exercise, reportedly since childhood. She experiences insomnia and requires physical exercise at bedtime (“100 sit-ups”) to sleep. Severe anxiety and panic attacks have been major life-long issues that have moderately improved on desipramine (50 mg/day since 1980). Desipramine also alleviated colitis-like symptoms. Her diet is high in animal protein, and its reduction or elimination results in perceived irritability. A peculiar rash with eczema- and psoriasis-like features, which had been present since early childhood and diagnosed in adolescence as eczema, responds to topical steroids. She has a widow’s peak (a V-shaped growth of hair in the center of the forehead). Cranial MRI identified the asymmetry of the ventricles and a reduction in cerebellum size [7].

T.G. has microdontia and hypodontia, including six missing adult teeth (two on bottom, four on top, bilaterally symmetrical) which are absent on x-ray; she did not lose the corresponding deciduous teeth until the third to sixth decades. Two dentists have
commented that she has a high arched palate. Additional ectodermal dysplasia (ED)-related manifestations include soft and very brittle nails, hyperhidrosis, and body hair loss since the fifth decade of life.

2.2. Sample and Genetic Analysis

We obtained written consent from T.G. to disclose her name and health information for this study and publication. We did not have access to parental samples. Genomic DNA was extracted from an oral swab (OC-100Dx, DNA Genotek, Kettawa, ON, Canada) using the PureGene extraction kit (Qiagen, Inc., Valencia, CA, USA). DNA extraction and all the analyses were performed in CAP and CLIA certified laboratories. Table 1 presents details regarding the various genetic testing technologies utilized in this study.

Table 1. Genetic testing methodologies utilized for Prof. Grandin in this study.

| Genetic Test                      | Technology                                                                 | Interpretation                                                                 |
|-----------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Chromosomal microarray (CMA)      | Custom-designed Affymetrix microarray                                      | Chromosome Analysis Suite v2.0.1 software (Thermo Fisher Scientific, Santa Clara, CA) |
|                                   | Enrichment: Ion AmpliSeq Exome Kit (Thermo Fisher Scientific)             |                                                                                |
|                                   | Sequencing: Ion Proton sequencing system (Thermo Fisher Scientific) with   |                                                                                |
|                                   | 200 bp amplicon read technology.                                          |                                                                                |
| Whole exome sequencing (WES)      | Genome Reference Consortium Human Build 37 (GRCh37, hg19) using the Ion     | Clinical Sequence Analyzer tool from WuXi NextCode (https://www.wuxinextcode.com) |
|                                   | Torrent Suite software v4.2 (Thermo Fisher Scientific)                     | Non-sense, missense and splice site variants were analyzed and were assessed for predicted deleterious effects using the Variant Effect Predictor (VEP) score [9]. |
| Whole genome sequencing (WGS)     | 2 × 150 bp reads on Illumina next-generation sequencing systems (mean coverage of 30x in the target region, including coding exons and 10 bp of flanking intronic sequence of the known protein-coding Ref-Seq genes) | Primary data analysis: Illumina DRAGEN Bio-IT Platform v2.03, interpreted on internal proprietary software from Variantyx, Framingham, MA, USA. Secondary and tertiary data analysis: Internal laboratory systems and Biodiscovery’s NxClinical v4.3 or Illumina DRAGEN Bio-IT Platform v2.03 for CNV and absence of heterozygosity. Detection and annotation of structural variants: The variants were called and annotated using Variantyx Genomic Intelligence structural variant pipeline [10]. |

Caption. ^1^ Affymetrix CytoScan-HD microarray plus 88,435 custom probes added to improve detection of copy number variants (CNVs) associated with neurodevelopmental disorders [8]. ^2^ Default settings used >97% coverage of 22,000 genes in the genome at >30x.

3. Results

In our testing population on the aforementioned custom array, we have historically observed that 28% of patients with neurodevelopmental disorders have one or more abnormal or potentially abnormal copy number variants (CNVs) [11]. In the case of T.G., we did not identify any pathogenic or likely pathogenic CNVs on either custom CMA or WGS, as reported through our clinical pipeline and ACMG reporting criteria [12], and the results were consistent with a normal female chromosome complement. However, out of over 4000 structural variants of different types (including deletions, duplications, inversions, LOH, break points, and insertions of transposable elements; see Table S2 for complete list) some of the variants of unknown significance could be relevant to patient’s phenotype given their relevance to brain pathology. Two of these variants are discussed in more detail below, both being located on the q arm of chromosome 9.

One of them, a heterozygous duplication of chr9q34.3q34.3x3(138,014,000–138,228,000) is about 200 kbp long and it includes several noncoding genes and exons 19 to 47 of a calcium channel gene CACNA1B. CACNA1B is associated with Neurodevelopmental
disorder with seizures and nonepileptic hyperkinetic movements, according to OMIM. The disease is autosomal recessive, and while the deletion has a 0.00035 allele frequency in general population (four cases out of 11,295 in DGV database), one cannot completely exclude mild phenotype in heterozygotes.

Another candidate structural variant is a 1656 bp heterozygous deletion of chr9q34.13q34.13 x1(131,153,102–131,154,758), which is not found in the general population. The deletion affects exon 3 of non-coding gene RP11-544A12.4. Interestingly, this gene overlaps NUP214, which is located on the opposite DNA strand and, according to OMIM, is associated with susceptibility to acute infection-induced encephalopathy-9. However, the facts that disease is recessive and for NUP214 the deletion is entirely intronic suggest that this variant is a less feasible candidate to be causative, at least not by itself.

WGS interpretation also revealed that CGG repeats that correspond to fragile X syndrome are 30,30 (a frequent normal genotype).

Three sequence variants of interest were identified in suspected or known ASD risk genes SHANK2, ALX1, and RELN (Table 2). Nevertheless, as of November 2020, none of these variants met the ACMG guidelines for “pathogenic” or “likely pathogenic” designation and, thus, are clinically classified as variants of uncertain significance (VUS) [12]. A heterozygous missense variant in SHANK2 (p.H64R) was identified. This missense variant is a change from histidine to arginine. The histidine at this location does not lie in any well-defined protein domains. However, histidine is present at this location in primates. Further, the substitution of histidine to arginine is predicted by SIFT to be deleterious. This suggests that the histidine amino acid substitution may alter protein function. Additionally, the variant is only observed in seven of 184,874 reference alleles (allele frequency: $3.79 \times 10^{-5}$) in the Genome Aggregation Database, a database of approximately 141,000 individuals without severe genetic conditions (gnomAD) [13,14]. Several studies suggest a role for SHANK2 in ASD and/or intellectual disability (ID). In one publication, a patient with ASD harbored a de novo nonsense variant in SHANK2, while two additional, unrelated patients with ASD and mild-to-moderate intellectual disability had de novo deletions in SHANK2 [15]. This study suggests that the haploinsufficiency of the SHANK2 gene may affect synaptic function and predispose to ASD and/or ID. In a subsequent study, a novel de novo SHANK2 deletion was identified in another patient with ASD. Further, sequencing identified a significant enrichment of variants affecting conserved amino acids in SHANK2 (3.4% of autism cases and 1.5% of controls, $P = 0.004$, OR = 2.37) [16]. In neuronal cell cultures, the variants that were identified in patients were associated with reduced synaptic density at dendrites when compared to variants that were only detected in controls. Interestingly, the three patients with de novo deletions identified in the two aforementioned studies also carry inherited CNVs at 15q11-q13 previously associated with neuropsychiatric disorders [17–19]. These data strengthen the role of synaptic gene dysfunction in ASD and support the "multiple hit model", suggesting that a better knowledge of these genetic interactions will be important in understanding the complex inheritance pattern of ASD [18,20].

A heterozygous missense variant (p.R64L) was identified in the ALX1 gene. ALX1 encodes a transcription factor that plays a role in development, including proper neural crest migration in animal models [21]. Bi-allelic loss-of-function variants in ALX1 cause frontonasal dysplasia, while gain-of-function variants are hypothesized to impact neurodevelopment [22,23]. T.G.’s craniofacial finding of a “widow’s peak” could be related to this variant, as neural crest cells can be found in hair follicles [24]. This variant was found in 1203 of the 280,730 reference alleles (allele frequency: 0.004285) in the gnomAD database [14]. Additionally, the variant identified in T.G. was one of several potential ASD risk variants that were identified in two unrelated multiplex families [25]. In one family, this variant was shared by two siblings with ASD and it was inherited from their unaffected father. In the second family, the variant was found in an individual with ASD and it was not found in his two brothers with ASD, but was inherited from his unaffected father. Importantly, reportedly unaffected parents were not phenotyped in detail in that publication.
The authors showed the ALX1 variant was observed multiple times in their population study (27/1541 cases and 58/5785 controls), yielding an odds ratio of 1.75 (95% confidence interval 1.11 to 2.77; \( p = 0.022 \); on page 7 of Matsunami et al., 2014 [25]). Although this specific variant has been observed in a supposedly unaffected control population, its higher prevalence in individuals with ASD when compared to those without ASD supports it as a potential risk factor. Further research is needed in order to confirm the impact of this variant on gene function and the role of ALX1 in ASD susceptibility.

A heterozygous missense variant in the RELN gene (p.T1002S) was also identified in T.G. RELN encodes the reelin protein, which is thought to control interactions between cells for cell positioning and neuronal migration. Although the serine for threonine substitution is conservative and does not lie within any known protein domain, this variant was not present in the gnomAD database and it is conserved across different vertebrate species, except lamprey (PhyloP 1.048) [14]. Variants in RELN are associated with autosomal recessive lissencephaly with cerebellar hypoplasia (OMIM). In addition, de novo variants in RELN have been observed in individuals with ASD in several studies [26–28].

MEFV is a fourth gene that harbored variants with clinical overlap for T.G. Two heterozygous variants, p.R408Q and p.P369S, were identified in T.G. and they have been reported to be disease-associated. Allele frequencies in the gnomAD database are 0.00001595 (four out of 250,794 reference alleles) and 0.01470 (4150 out of 282,228 reference alleles, respectively [14]. The MEFV gene encodes a protein, called pyrin, whose function is not fully understood, but appears to direct the migration of white blood cells to sites of inflammation and downregulate the inflammatory response following the improvement of infection or injury. Over 80 variants in MEFV have been associated with familial Mediterranean fever (FMF), a highly complex and variable condition that can exhibit either autosomal dominant or autosomal recessive inheritance [29]. Studies suggest these variants are in linkage disequilibrium and are, thus, in cis [30]; indeed, a review of the WGS read data that were utilized in this study (2 \( \times \) 150 bp) was long enough to confirm cis phasing. Despite having ClinVar associations that range from “benign” to “pathogenic”, these variants, when found together, have been published as associated with disease and they are often included in clinical gene panels that are designed to test for FMF [31,32]. Most of the patients with both variants are reported to have an atypical clinical presentation. Although T.G. does not strictly meet the Tel-Hashomer clinical criteria for FMF, she has symptoms that are consistent with the atypical presentation of the condition seen in those with the same genotype, including frequent intermittent hot spells, muscles that are stiff and sore, episodes of calor, and paresthesia in both feet, and lifelong skin rashes that are diagnosed as eczema [32]. FMF has not been reported to be associated with ASD; however, inflammation is one of many pathways implemented in ASD pathogenesis and, thus, we cannot exclude these variants as being risk factors for ASD in T.G.

Further, WNT10A is another gene harboring a variant with overlap to T.G.’s phenotype. A homozygous variant (p.F228I) has been previously reported as pathogenic. WNT10A is a member of the WNT gene family, which encodes proteins that are implicated in several developmental processes, including the regulation of cell fate and patterning during embryogenesis [33]. Although p.F228I is a conservative amino acid substitution, the amino acid at this position is conserved across different species (PhyloP 0.964) and the variant has been predicted to be deleterious to the protein structure or function by in silico prediction tools. The variant identified here has been reported previously, either in the homozygous state or in trans with a second pathogenic variant, in individuals with either isolated oligodontia, tooth agenesis, or with other features of ED [34–38]. The p.F228I variant that is identified in T.G. is observed at a relatively high frequency in the general population (heterozygous carrier frequency: 0.0137, homozygote frequency: 0.000153 in the gnomAD database) [14]. Oligodontia is observed in approximately 0.14% of the population and, in one study, it was shown that variants in WNT10A were present in more than half of the cases of isolated oligodontia [38,39]. The variant in WNT10A possibly explains the multiple ED-like manifestations in T.G. involving her teeth, nails, hair, and sweat glands.
Table 2. Rare missense variants that are potentially relevant to T.G.’s phenotype, identified on both whole exome and whole genome sequencing.

| Gene | Chromosome [GRCh37] | ISCN | HGVS Protein Reference | SIFT Predicted Effect | Clinical Classification | dbSNP/dbVar ID | gnomAD Allele Frequency (v2.1.1; GRCh37) | Genotype in T.G. | Symptoms with Overlap |
|------|----------------------|------|------------------------|-----------------------|-------------------------|---------------|---------------------------------|----------------|----------------------|
| 1    | ALX1                 | 12: 85674230 | NM_006982.3:c.191G>T | p.Arg64Leu            | Deleterious             | VUS           | rs115596276                     | 0.004285 | Het                  | ASD             |
| 2    | RELN                 | 7: 103251145 | NM_005045.4:c.3005C>G | p.Thr1002Ser          | Tolerable               | VUS           | rs1376812440                    | NA            | Het                  | ASD             |
| 3    | SHANK2               | 11:70858182 | NM_012309.4:c.191T>C   | p.His64Arg            | Deleterious             | VUS           | rs200995537                     | 0.0000379 | Het                  | ASD             |
| 4    | MEFV                 | 16: 3299468 | NM_000243.3:c.1223G>A  | p.Arg408Gln           | Tolerable               | Pathogenic     | rs11466024                      | 0.00001595 | Het                  | FMF             |
| 5    | MEFV                 | 16: 3299586 | NM_000243.3:c.1105C>T  | p.Pro369Ser           | Deleterious             | Pathogenic     | rs11466023                      | 0.01470    | Het                  | FMF             |
| 6    | WNT10A               | 2:219755011 | NM_025216.3:c.682T>A   | p.Phe228Ile           | Deleterious             | Pathogenic     | rs121908120                     | 0.0137     | Homo                 | ED              |

Caption. VUS-variant of uncertain clinical significance; NA-not available; Het-Heterozygous; Homo-Homozygous; ASD-autism spectrum disorder; FMF-familial Mediterranean fever; ED-ectodermal dysplasia; rows 1–3 strong evidence to support autism susceptibility; rows 4–6 lists published pathogenic variants with excellent clinical correlation. Based on review of WGS raw data, MEFV variants are in cis. Note: VKORC1 and CYP2C9 variants described in the text are polymorphisms and thus not represented in the rare variant table above.
Please see Supplementary Table S1 for additional variants, which were identified in both the whole exome and whole genome sequencing assays that were run independently, with additional clinical overlap that potentially contributes to T.G.’s ASD, sleep pathogenesis, anxiety, mitochondrial function, and more, including some with potential therapeutic targets.

From a proactive standpoint, sequencing also identified a CYP2C9 genotype that was associated with slowed metabolism of many drugs, including the anticoagulant warfarin [40]. This information, coupled with T.G.’s heterozygous status of the VKORC1 1639G>A variant also revealed by this testing, provides specific dosing information if warfarin is prescribed to reduce the risk adverse events. Furthermore, this CYP2C9 genotype is also correlated with slowed metabolism of the anti-epileptic drug phenytoin, which would impact the dosing recommendations; this is critical information, given that there is a high rate of comorbidity between epilepsy/seizures and ASD [41,42].

Given the presence of multiple genetic variants potentially contributing to the manifestation of ASD in T.G., we sought to explore her data through a currently available polygenic risk score (PRS) algorithm (impute.me). This algorithm showed that T.G.’s PRS for ASD is lower than 99% and greater than 1% of the general population by assessing 17 single nucleotide polymorphisms (SNPs) that were previously reported to be associated with ASD [43].

4. Discussion

We present this case of a female scientist, Prof. Temple Grandin, with high-functioning ASD and other clinical sequelae, who was referred for clinical diagnostic testing. Through various test methodologies, we identified variants of unknown significance in three ASD risk genes (SHANK2, ALX1, and RELN) and other variants that impact genes that are possibly relevant to ASD pathology. This supports the concept of a polygenic model in ASD. Surprisingly, the PRS model used for T.G. showed her risk for ASD in the 1st centile of the general population. The tool did provide a pie chart indicating that the genetic liability captured by this assessment is very small (~1%), which echoes the disclaimer supplied in other publications regarding the limitations of PRS for clinical application [44]. There are several potential reasons for the contradictory ASD PRS score in T.G., given her clinical diagnosis. The SNPs that were used to generate the score in the impute.me tool were derived from case cohort individuals diagnosed with ASD prior to 2014 [43]. Importantly, Asperger disorder was a diagnostic entity until 2013, according to the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM). Therefore, the case cohort whose data are represented in the tool is likely more representative of those individuals who are lower functioning, which is in stark contrast to the phenotype of T.G. Additionally, we, as a community, do not yet know all of the genes and variants contributing to ASD. Additionally, finally, some co-occurring traits in those with ASD are also clearly polygenic (IQ and anxiety for instance) and may skew the algorithmic outcomes. In summary, a low PRS score, at least for ASD, cannot be used to rule out the potential for a future clinical diagnosis.

While T.G. herself does not harbor any known, identifiable ASD-related variants that garner specific medical management changes, this is a possibility for others with ASD and genetic testing should be pursued as a standard of care in line with ACMG and other medical guidelines [45]. Importantly, genetic testing did identify actionable variants that contribute to T.G.’s clinical symptomatology and can be specifically addressed in order to improve her functional symptoms and prevent further medical issues. Of note, prior to testing, additional neurological and non-neurological symptoms were attributed to a broader diagnosis of ASD and not specifically addressed based on underlying genetic etiology. This is critical for medical action, as well as family understanding, coping, and improved quality of life.

For example, clinical features that disturb T.G.’s activities of daily living are longstanding calor and paresthesia in both feet. These correlate with the two identified MEFV variants that were reported in cases with atypical familial Mediterranean fever. FMF is a
treatable condition, and T.G. has since been referred to see a specialist. In addition, the homozygous pathogenic variant in \textit{WNT10A} is likely to explain T.G.’s multiple ED-related symptoms. Dentists and orthodontists incorporate specific management decisions for individuals with ED-related disorders. Fortunately, T.G. herself chose not to have dental implants; the avoidance of dental implants would have been advised previously had a diagnosis of ED been known at the time. Moreover, genetic testing has provided actionable guidelines for the future prescription of certain pharmacologic treatments that were impacted by \textit{CYP2C9} metabolism. There are a variety of other findings for T.G. with currently less well-supported medical literature that will advance with time. For example, will some combination of CNVs and SNVs that are currently classified as benign emerge as a risk susceptibility for ASD? In the future, will the reclassification of VUS to pathogenic or likely pathogenic variants trigger medical action that prevents medical morbidity or mortality? A reinterpretation of the raw data and integration with medical care can be pursued based on T.G.’s medical course and preferences in the future.

The power of clinically available genetic testing for those with ASD with or without co-occurring morbidities can be substantial for neurologic and non-neurologic precision medicine, as shown in this study. However, there are associated challenges that we must address as a medical community to make this process more impactful. One is a lack of trained clinical experts that are comfortable in reading vast amounts of genetic data and translating it in order to inform disease-associated factors and treatment options. Efforts should be made to train physicians and other healthcare providers in the practical use of genomics, as the future of health care depends on its understanding and application, including the limitations of using PRS models to predict future presence and severity for ASD. A second challenge is that the feasibility of a “genomics board” (akin to that of a multidisciplinary “tumor board”, which is standard in oncologic care) is hindered by state medical licensing and telemedicine laws. Genetic counselors (GCs) are essential in this process and growing in number, but they typically have long wait lists or their own state licensure barriers that encumber integrated care. Peer-to-peer consultation between physicians and GCs is not precluded by such laws; however, including the family in the discussion constitutes the practice of medicine in most jurisdictions. Third, market forces have resulted in low-cost exome and genome testing. However, careful report generation and detailed discussion with the patient’s attending providers takes substantial professional time and it is not practical under the current cost structures. Paradoxically, this results in healthcare providers being unaware of or unable to utilize the resulting complex genetic reports in order to improve clinical care and leads insurance companies to deny coverage for lack of clinical application. We propose that payer policies should be devise to commensurately compensate parties that are involved in sequencing and variant interpretation, as well as physicians and GCs for effective use of the data and the treatment of the patients.

To summarize, these data support the concept that the genetic etiology of high-functioning ASD in T.G. could result from a combination of multiple genetic factors interacting in order to yield the observed clinical features. We demonstrated that comprehensive clinical phenotype information and genomics-trained providers/laboratorians are critical in the interpretation of genomic variants that were identified through these high-throughput genomic technologies. The genomic analysis that was carried out in this study provides a basis for at least part of T.G.’s clinical features and delivers suggestions for effective management of some of the symptoms. While improvements can be made to the process and application of genetic testing for individuals with ASD, it is effective and critical, as it currently exists for optimal medical and improved personal and family quality of life.

\textbf{Supplementary Materials:} The following are available online at https://www.mdpi.com/2075-4266/11/1/21/s1, Table S1: Detailed Sequence Variant Spreadsheet, Table S2: Detailed Structural Variant Spreadsheet.
Author Contributions: Conceptualization, R.J.V., C.H.H., E.R.W., T.G., R.G.B.; resources, R.J.V., L.S., E.R.W., T.G., R.G.B.; data curation, A.P., M.A.S., A.K.; writing—original draft preparation, R.J.V., A.P.; writing—review and editing, R.J.V., A.P., L.S., M.A.S., R.G.B.; visualization, R.J.V., E.R.W., T.G., A.K., R.G.B.; supervision, R.J.V., C.H.H., E.R.W., R.G.B.; project administration, R.J.V.; funding acquisition, R.J.V., C.H.H., E.R.W., T.G., R.G.B. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by Lineagen, Inc.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by Western Institutional Review Board (protocol code 20162032 and date of approval 11/1/2018).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available in the supplemental materials of this manuscript submission.

Acknowledgments: We thank members of our CAP/CLIA laboratory partners (including Predictive Laboratories, formerly known as Taueret Laboratories, LLC and PerkinElmer Genomics) for their assistance in processing and analyzing this sample and the team at Variantyx, Inc. for providing access to its Genomic Intelligence® software for WGS analysis. We also thank Jehannine Austin for providing expert guidance regarding the impute.me website and utility of polygenic risk scores as well as the entire Lineagen team for upholding our vision and mission to improve the lives of all individuals with autism spectrum disorder.

Conflicts of Interest: A.P., C.H.H., E.R.W., and L.S. were employees of Lineagen. M.A.S. and R.J.V. are employees and shareholders of Bionano Genomics, Lineagen’s owner. A.K. is an employee and shareholder of Variantyx, Inc. T.G. and R.G.B. have no conflicts to declare.

References
1. Veenstra-Vanderweele, J.; Christian, S.L.; Cook, E.H. Autism as a paradigmatic complex genetic disorder. *Annu. Rev. Genom. Hum. Genet.* 2004, 5, 379–405. [CrossRef] [PubMed]
2. Schaefer, G.B.; Mendelsohn, N.J.; Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. *Genet. Med. Off. J. Am. Coll. Med. Genet.* 2013, 15, 399–407. [CrossRef] [PubMed]
3. Çöp, E.; Yurtbaşi, P.; Öner, Ö.; Münnir, K.M. Genetic testing in children with autism spectrum disorders. *Anadolu Psikiyatr. Derg.* 2015, 16, 426–432. [CrossRef] [PubMed]
4. Kanner, L. Autistic disturbances of affective contact. *Nero: Child* 1943, 2, 217–250.
5. Grandin, T. *Thinking in Pictures: And Other Reports from My Life with Autism*, 1st ed.; Doubleday: New York, NY, USA, 1995.
6. Grandin, T. How does visual thinking work in the mind of a person with autism? A personal account. *Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci.* 2009, 364, 1437–1442. [CrossRef]
7. Grandin, T.; Panek, R. *The Autistic Brain*; Houghton Mifflin Harcourt: New York, NY, USA, 2013.
8. Hensel, C.; Vanzo, R.; Martin, M.; Dixon, S.; Lambert, C.; Levy, B.; Nelson, L.; Peiffer, A.; Ho, K.S.; Rushton, P.; et al. Analytical and Clinical Validity Study of FirstStepDx PLUS: A Chromosomal Microarray Optimized for Patients with Neurodevelopmental Conditions. *PLoS Curr.* 2017, 9. [CrossRef]
9. McLaren, W.; Pritchard, B.; Rios, D.; Chen, Y.; Flicek, P.; Cunningham, F. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. *Bioinformatics* 2010, 26, 2069–2070. [CrossRef]
10. Neerman, N.; Faust, G.; Meeks, N.; Modaj, S.; Kalfon, L.; Falik-Zaccai, T.; Kaplun, A. A clinically validated whole genome pipeline for structural variant detection and analysis. *BMC Genom.* 2019, 16, 545. [CrossRef]
11. Ho, K.S.; Wassman, E.R.; Baxter, A.L.; Hensel, C.; Martin, M.M.; Prasad, A.; Twede, H.; Vanzo, R.J.; Butler, M.G. Chromosomal Microarray Analysis of Consecutive Individuals with Autism Spectrum Disorders Using an Ultra-High Resolution Chromosomal Microarray Optimized for Neurodevelopmental Disorders. *Int. J. Mol. Sci.* 2016, 17, 2070. [CrossRef]
12. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hегde, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med. Off. J. Am. Coll. Med. Genet.* 2015, 17, 405–424. [CrossRef]
13. Ng, P.C.; Henikoff, S. Predicting deleterious amino acid substitutions. *Genome Res.* 2001, 11, 863–874. [CrossRef] [PubMed]
14. Lek, M.; Karczewski, K.J.; Minikel, E.V.; Samocha, K.E.; Banks, E.; Fennell, T.; O’Donnell-Luria, A.H.; Ware, J.S.; Hill, A.J.; Cummings, B.B.; et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 2016, 536, 285–291. [CrossRef] [PubMed]
15. Berkel, S.; Marshall, C.; Weiss, B.; Howe, J.L.; Roeth, R.; Moog, U.; Endris, V.; Roberts, W.; Szatmari, P.; Pinto, D.; et al. Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nat. Genet. 2010, 42, 489–491. [CrossRef] [PubMed]

16. Leblond, C.S.; Heinrich, J.; Delorme, R.; Proepper, C.; Betancur, C.; Huguet, G.; Konyukh, M.; Chaste, P.; Ey, E.; Rastam, M.; et al. Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders. PLoS Genet. 2012, 8, e1002521. [CrossRef] [PubMed]

17. Bucan, M.; Abrahams, B.S.; Wang, K.; Glessner, J.T.; Herman, E.I.; Sonnenblick, L.I.; Retuerto, A.L.A.; Imieliński, M.; Hadley, D.; Bradford, J.P.; et al. Genome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genes. PLoS Genet. 2009, 5, e1000536. [CrossRef] [PubMed]

18. Stewart, L.R.; Hall, A.L.; Kang, S.-H.L.; Shaw, C.A.; Beaudet, A.L. High frequency of known copy number abnormalities and maternal duplication 15q11-q13 in patients with schizophrenia and epilepsy. BMC Med Genet. 2011, 12, 154. [CrossRef]

19. Ingason, A.; Kirov, G.; Giegling, I.; Hansen, A.R.; Jakobsen, K.D.; Kristinsson, K.T.; Le Roux, L.; Gustafsson, O.; Craddock, N.; et al. Maternally derived microduplications at 15q11-q13: Implication of imprinted genes in psychotic illness. Am. J. Psychiatry 2011, 168, 408–417. [CrossRef]

20. Guo, H.; Wang, T.; Wu, H.; Long, M.; Coe, B.P.; Li, H.; Xun, G.; Ou, J.; Chen, B.; Duan, G.; et al. Inherited and multiple de novo mutations in autism / developmental delay risk genes suggest a multifactorial model. Mol. Autism 2018, 9, 64. [CrossRef]

21. Dee, C.T.; Szymoniuk, C.R.; Mills, P.E.D.; Takahashi, T. Defective neural crest migration revealed by a Zebrafish model of familial Mediterranean fever. Arthritis Rheum. 2004, 5, 789–796. [CrossRef]

22. Liao, H.-M.; Fang, J.-S.; Chen, Y.-J.; Wu, K.-L.; Lee, K.-F.; Chen, C.-H. Clinical and molecular characterization of a transmitted reciprocal translocation t(1;12)(p32.1;q21.3) in a family co-segregating with mental retardation, language delay, and microcephaly. BMC Med Genet. 2011, 12, 70. [CrossRef] [PubMed]

23. Liao, H.-M.; Fang, J.-S.; Chen, Y.-J.; Wu, K.-L.; Lee, K.-F.; Chen, C.-H. Clinical and molecular characterization of a transmitted reciprocal translocation t(1;12)(p32.1;q21.3) in a family co-segregating with mental retardation, language delay, and microcephaly. BMC Med Genet. 2011, 12, 70. [CrossRef] [PubMed]

24. Sieber-Blum, M.; Grim, M.; Hu, Y.F.; Szyder, V. Pluripotent neural crest stem cells in the adult hair follicle. Dev. Dyn. Off. Publ. Am. Assoc. Anat. 2004, 231, 258–269. [CrossRef]

25. Matsunami, N.; Hensel, C.; Baird, L.; Stevens, J.; Otterud, B.; Leppert, T.; Varvil, T.; Hadley, D.; Glessner, J.; Pellegrino, R.; et al. Identification of rare DNA sequence variants in high-risk autism families and their prevalence in a large case/control population. Mol. Autism 2014, 5, 5. [CrossRef] [PubMed]

26. De Rubeis, S.; Menachem, E.; Goldberg, A.P.; Poutney, C.S.; Samocha, K.; Cicic, A.E.; Kou, Y.; Liu, L.; Fromer, M.; Walker, S.; et al. Synaptic transcriptional and chromatin genes disrupted in autism. Nature 2014, 515, 209–215. [CrossRef] [PubMed]

27. Iossifov, I.; Ronemus, M.; Levy, D.; Wang, Z.; Hakker, I.; Rosenbaum, J.; Yamrom, B.; Lee, Y.-H.; Narzisi, G.; Leotta, A.; et al. De novo gene disruptions in children on the autistic spectrum. Neuron 2012, 74, 285–299. [CrossRef] [PubMed]

28. Stessman, H.A.F.; Xiong, B.; Coe, B.P.; Wang, T.; Hoekzema, K.; Fencikova, M.; Kvarnung, M.; Gerdts, J.; Trinh, S.; Cosemans, N.; et al. Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases. Nat. Genet. 2017, 49, 515–526. [CrossRef] [PubMed]

29. Shohat, M. Familial Mediterranean Fever. In GeneReviews® [Internet]; Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Stephens, K., Amemiya, A., Eds.; University of Washington: Seattle, WA, USA, 2000. Available online: http://www.ncbi.nlm.nih.gov/books/NBK1227/ (accessed on 16 December 2019).

30. Ryan, J.G.; Masters, S.L.; Booty, M.G.; Habal, N.; Alexander, J.D.; Barham, B.K.; Remmers, E.F.; Barron, K.S.; Kastner, D.L.; Aksentijevich, I. Clinical features and functional significance of the P369S/R408Q variant in pyrin, the familial Mediterranean fever gene. Arthritis Rheum. 1997, 40, 1879–1885. [CrossRef]

31. Lee, H.-Y.; Kleber, M.; Hari, L.; Braunitz, P.; Suter, U.; Taketo, M.; Kerler, M.; Sommer, L. Instructive role of Wnt/beta-catenin in sensory fate specification in neural crest stem cells. Science 2004, 303, 1020–1023. [CrossRef]

32. Bohring, A.; Stamm, T.; Spaich, C.; Haase, C.; Spree, K.; Heer, U.; Hoffmann, M.; Ledig, S.; Sel, S.; Wieacker, P.; et al. WNT10A mutations are a frequent cause of a broad spectrum of ectodermal dysplasias with sex-biased manifestation pattern in heterozygotes. Ann. Hum. Genet. 2009, 85, 97–105. [CrossRef] [PubMed]

33. Dinckan, N.; Du, R.; Petty, L.; Coban-Akdemir, Z.; Jiangiani, S.; Paine, I.; Baugh, E.; Erdem, A.; Kayserili, H.; Doddapaneni, H.; et al. Whole-Exome Sequencing Identifies Novel Variants for Tooth Agenesis. J. Dent. Res. 2018, 97, 49–59. [CrossRef] [PubMed]

34. Kantaputra, P.; Sripathsomsawat, W. WNT10A and isolated hypodontia. Am. J. Med Genet. Part A 2011, 155A, 1119–1122. [CrossRef] [PubMed]

35. Plaisancé, J.; Bailleul-Forestier, I.; Gaston, V.; Vaysse, F.; Lacombe, D.; Holder-Espinasse, M.; Abramowicz, M.; Coubes, P.; Plessis, G.; Faivre, L.; et al. Mutations in WNT10A are frequently involved in oligodontia associated with minor signs of ectodermal dysplasia. Am. J. Med Genet. Part A 2013, 161A, 671–678. [CrossRef] [PubMed]
38. van den Boogaard, M.-J.; Créton, M.; Bronkhorst, Y.; van der Hout, A.; Hennekam, E.; Lindhout, D.; Cune, M.; Ploos van Amstel, H.K. Mutations in WNT10A are present in more than half of isolated hypodontia cases. *J. Med Genet.* 2012, 49, 327–331. [CrossRef] [PubMed]

39. Nieminen, P. Genetic basis of tooth agenesis. *J. Exp. Zool. Part B Mol. Dev. Evol.* 2009, 312B, 320–342. [CrossRef] [PubMed]

40. JoJohnson, J.A.; Caudle, K.E.; Gong, L.; Whirl-Carrillo, M.; Stein, C.M.; Scott, S.A.; Lee, M.T.M.; Gage, B.F.; Kimmel, S.E.; Perera, M.A.; et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. *Clin. Pharmacol. Ther.* 2017, 102, 397–404. [CrossRef]

41. Caudle, K.E.; Rettie, A.E.; Whirl-Carrillo, M.; Smith, L.H.; Mintzer, S.; Lee, M.T.M.; Klein, T.E.; Callaghan, J.T. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. *Clin. Pharmacol. Ther.* 2014, 96, 542–548. [CrossRef]

42. Sundelin, H.E.K.; Larsson, H.; Lichtenstein, P.; Almqvist, C.; Hultman, C.M.; Tomson, T.; Ludvigsson, J.F. Autism and epilepsy: A population-based nationwide cohort study. *Neurology* 2016, 87, 192–197. [CrossRef]

43. Grove, J.; Ripke, S.; Als, T.D.; Mattheisen, M.; Walters, R.K.; Won, H.; Pallesen, J.; Agerbo, E.; A Andreassen, O.; Anney, R.; et al. Identification of common genetic risk variants for autism spectrum disorder. *Nat Genet.* 2019, 51, 431–444. [CrossRef]

44. Wray, N.R.; Lin, T.; Austin, J.; McGrath, J.J.; Hickie, I.B.; Murray, G.K.; Visscher, P.M. From Basic Science to Clinical Application of Polygenic Risk Scores: A Primer. *JAMA Psychiatry* 2020. [CrossRef] [PubMed]

45. Henderson, L.B.; Applegate, C.D.; Wohler, E.; Sheridan, M.B.; Hoover-Fong, J.; Battista, D.A.S. The impact of chromosomal microarray on clinical management: A retrospective analysis. *Genet. Med. Off. J. Am. Coll. Med Genet.* 2014, 16, 657–664. [CrossRef] [PubMed]